Contineum Therapeutics, Inc.
NASDAQ: CTNM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carmine N. Stengone
- Employees
- 51
- Headquarters
- San Diego, United States
- IPO year
- 2024
- Market cap
- $479.3M
- Website
- https://www.contineum-tx.com
Loading CTNM…
Loading profile data…Frequently asked questions about CTNM
What does Contineum Therapeutics, Inc. (CTNM) do?
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (L...
Where does CTNM trade?
Contineum Therapeutics, Inc. (CTNM) trades on the NASDAQ.
What sector is CTNM in?
Contineum Therapeutics, Inc. (CTNM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Contineum Therapeutics, Inc.?
Carmine N. Stengone is the chief executive officer of Contineum Therapeutics, Inc. (CTNM).
Where is Contineum Therapeutics, Inc. headquartered?
Contineum Therapeutics, Inc. is headquartered in United States.
Does CTNM pay a dividend?
Contineum Therapeutics, Inc. (CTNM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CTNM go public?
Contineum Therapeutics, Inc. (CTNM) completed its initial public offering in 2024.